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In this age of Internet access to vast online medical reference data-
bases, one has to ask what encourages the ownership of medical
books. Three outstanding reasons are the wish to have a compre-
hensive reference work, an introduction to a new subject or the
analysis or metanalysis of an overcrowded literature. ‘Malignant
Lymphomas’ in the American Cancer Society series belongs to
the last of these three categories. It is not a reference work, which
is surprising for a series entitled the ‘Atlas of Clinical Oncology’.
For a reference work there are just too many missing topics that
one would expect to have been covered. Some lymphomas, such
as chronic lymphocytic leukaemia, hairy cell leukaemia, adult T cell
leukaemia/lymphoma or post-transplant lymphoproliferative
disease may have been left to be dealt with by other books in
the series. However, the absence of lymphoplasmacytoid lympho-
ma, myeloma, splenic marginal zone and anaplastic large cell
lymphoma can hardly be regarded as oversights and the lack of
any coverage of the T cell lymphomas except for mycosis
fungoides/Sezary’s syndrome is a glaring omission. On the other
hand, it is too detailed to be an introduction to malignant lympho-
mas for the novice.
What ‘Malignant Lymphomas’ covers, with a few exceptions, are
the commonest types of B cell lymphoma and Hodgkin’s disease.
The ﬁrst chapter deals with histopathology of lymphomas and this
chapter underlines how many lymphoma categories are missing
from this book. It also illustrates one of the problems within the
structure of the book, a perennial problem for non-Hodgkin’s
lymphoma, which is lymphoma classiﬁcation. The recent WHO
classiﬁcation, based on the REAL classiﬁcation, has been chosen
as the basis upon which ‘Malignant Lymphomas’ should be
analysed. Clinicians have become so nervous about lymphoma clas-
siﬁcation, that almost every chapter thereafter gives a potted
version of lymphoma histopathology and being unprepared to
analyse their clinical data in terms of the new classiﬁcation usually
revert thereafter to the use of broad categories such as ‘Indolent’
and ‘Aggressive’ lymphomas, neither of which should have any
place in the WHO classiﬁcation. The photomicrographs used to
illustrate pathology in the ﬁrst chapter are generally too underex-
posed but usually interpretable whereas in other chapters they
can be uninterpretable because of the underexposure. The follow-
ing chapters on Epidemiology and Molecular Biology adequately
cover the scientiﬁc basis of lymphomas while chapters on Staging
and Prognostic factors cover the clinical science. Thereafter the
analysis of lymphomas is largely broken down into three main clin-
ical categories – Indolent, Diffuse Large Cell and High-Grade
lymphomas with two chapters devoted to the special circumstances
of lymphomas in AIDS and the elderly. There are odd chapters on
MALT, mantle cell and primary mediastinal lymphomas but these
seem to be special side-shows rather than part of a systematic
coverage. It is odd that neither the Epidemiology nor MALT chap-
ters examine the aetiological and biological signiﬁcance of
Helicobacter pylori. The management of the three main clinical
sections is dealt within the chapters attributed to them and then
special aspects are revisited by chapters on High Dose Therapy,
Stem Cell Transplantation, Salvage Chemotherapy and Monoclonal
antibody therapy. These sections overlap each other and continue
to undermine any attempt to make the subject consistent with
the WHO classiﬁcation. Although there is a wealth of information
and reference in these clinical chapters, it leaves one with the
strong impression that they are based around the expertise of indi-
vidual authors rather than a systematic, science driven plan. This
lack of co-ordination and integration has to be due to the editorial
policy behind the book and ought to be reconsidered in future
editions.
In essence this book has been mainly constructed to put into
biological context a review of clinical trials and lymphoma manage-
ment using different cytotoxic chemotherapy regimes with or
without autologous or allogeneic stem cell rescue. There is a dearth
of any information peripheral to the therapeutic management of
lymphomas. For example, the immunological effects of lymphoma,
such as autoimmune haemolytic anaemia, immunodeﬁciency or
opportunistic infection are not even mentioned. Even the manage-
ment or strategy for dealing with neutropoenic sepsis is not
addressed outside of the inclusion of G-CSF into drug regimens
to prevent neutropoenia. In this way the book is very narrowly
focussed and will consequently provide a useful summary of the
current status of therapy for common lymphomas for medical,
clinical and haemato-oncologists.
In conclusion, this book is suitable for those who wish to get a
concise scientiﬁc background to lymphomas and obtain a fairly up
to date review of the medical oncological management of the
common clinical forms of lymphoma and Hodgkin’s disease.
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